StockIQpro
NASDAQ:CNSP

CNS Pharmaceuticals, Inc.

Track all markets on TradingView
Track all markets on TradingView

CNS Pharmaceuticals, Inc. reported net income of −$15.9M in fiscal 2025. Free cash flow was −$13.8M, and the diluted share count rose 1293.2%.Summary generated from CNS Pharmaceuticals, Inc.'s SEC filings. Latest annual report filed Mar 31, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−296.3%
Debt / equityn/a
Free cash flow−$13.8M
FCF marginn/a
Share count change+1293.2%

Financials

Fiscal years, $M
Item20212022202320242025
Revenuen/an/an/an/an/a
Operating income−14−15−19−15−16
Net income−14−15−19−15−16
Free cash flow−14−11−14−17−14

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations